Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U1MO
|
|||
| Former ID |
DIB013821
|
|||
| Drug Name |
CERE-120
|
|||
| Synonyms |
Neurturin; NeuroRescue PD; AAV-NTN; AAV2-NRTN; AAV2-Neurturin; NTN gene therapy, Ceregene; Neurological gene therapy, Ceregene; Neurturin gene therapy, Ceregene; Neurturin, Genentech; Parkinsons disease gene therapy, Ceregene; GDNF agonist, StemCells/Genentech; NTN gene-expressing AAV vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme; Neurturin gene-expressing adeno-associated virus vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme
Click to Show/Hide
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 2 | [1], [2] | |
| Company |
Ceregene
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Netrin (NET) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5032). | |||
| REF 2 | ClinicalTrials.gov (NCT00400634) Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease. U.S. National Institutes of Health. | |||
| REF 3 | Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther. 2007 Jan;15(1):62-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.